An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses

(2020) Wenjie Zhai et al.   Acta Pharmaceutica Sinica B

A Novel D Peptide Identified by Mirror‐image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy

(2020) Xiuman Zhou et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Determination of Rufinamide in the Presence of 1-[(2,6-Difluorophenyl)Methyl]-1H-1,2,3-Triazole-4 Carboxylic Acid Using RP-HPLC and Derivative Ratio Methods as Stability Indicating Assays to Be Applied on Dosage Form

(2020) Sonia T Hassib et al.   JOURNAL OF AOAC INTERNATIONAL

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy

(2020) Hongfei Wang et al.   Journal for ImmunoTherapy of Cancer

PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway

(2019) Xufu Wang et al.   MOLECULAR IMMUNOLOGY

Excretion stereoselectivity of triticonazole in rat urine and faeces

(2019) Jing Nie et al.   JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART B-PESTICIDES FOOD CONTAMINANTS AND AGRICULTURAL WASTES

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)

(2018) Jiangfeng Du et al.   Cell Communication and Signaling

N -trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N -trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer

(2018) Guanyu Chen et al.   JOURNAL OF CONTROLLED RELEASE

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

(2018) Kui Li et al.   JOURNAL OF DRUG TARGETING

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

(2018) Fatemeh K. Dermani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules

(2018) Jeffrey Yang et al.   MEDICINAL RESEARCH REVIEWS

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-affinity human PD-L1 variants attenuate the suppression of T cell activation

(2017) Zhaoduan Liang et al.   Oncotarget

A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity

(2016) Yan Luan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy

(2016) Zhongyi Yan et al.   Oncotarget

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

(2016) Qiao Li et al.   Oncotarget

Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy

(2015) Hao-Nan Chang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues

(2015) Sandeep Singh et al.   Biology Direct

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Oral Absorption Promoters: Opportunities, Issues, and Challenges

(2015) Chetan Yewale et al.   CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin

(2015) Peiwen Zhang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies

(2015) Guanyu Chen et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers

(2014) B. G. Pierce et al.   BIOINFORMATICS

pH sensitive N-succinyl chitosan grafted polyacrylamide hydrogel for oral insulin delivery

(2014) Piyasi Mukhopadhyay et al.   CARBOHYDRATE POLYMERS

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

(2014) Alice L Smart et al.   Expert Opinion on Drug Delivery

Therapeutic applications of hydrogels in oral drug delivery

(2014) Lindsey A Sharpe et al.   Expert Opinion on Drug Delivery

Enhanced Oral Delivery of Curcumin from N-trimethyl Chitosan Surface-Modified Solid Lipid Nanoparticles: Pharmacokinetic and Brain Distribution Evaluations

(2014) Prakash Ramalingam et al.   PHARMACEUTICAL RESEARCH

Cancer immunotherapy

(2013) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

PD-1 as a potential target in cancer therapy

(2013) David F. McDermott et al.   Cancer Medicine

Development of an isocratic HPLC method for catechin quantification and its application to formulation studies

(2012) Danhui Li et al.   FITOTERAPIA

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy

(2012) Katarzyna Karwacz et al.   OncoImmunology

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

Enhanced transbuccal salmon calcitonin (sCT) delivery: Effect of chemical enhancers and electrical assistance on in vitro sCT buccal permeation

(2011) Dong-Ho Oh et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Drug delivery applications for superporous hydrogels

(2011) David J Mastropietro et al.   Expert Opinion on Drug Delivery

Accelerating Protein Docking in ZDOCK Using an Advanced 3D Convolution Library

(2011) Brian G. Pierce et al.   PLoS One

Insulin-Loaded Nanoparticles Based on N-Trimethyl Chitosan: In Vitro (Caco-2 Model) and Ex Vivo (Excised Rat Jejunum, Duodenum, and Ileum) Evaluation of Penetration Enhancement Properties

(2010) Giuseppina Sandri et al.   AAPS PHARMSCITECH

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic therapeutic peptides: science and market

(2009) Patrick Vlieghe et al.   DRUG DISCOVERY TODAY

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

Trimethyl chitosan and its applications in drug delivery

(2009) V. K. Mourya et al.   JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA